Intercure Ltd. (INCR)
INCR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2024-12-31, https://www.sec.gov/Archives/edgar/data/1857030/000164117225007971/0001641172-25-007971-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2024-12-31. Converted from ILS at 3.0766 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | INCR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0001857030 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | L3 |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $77.6M |
| Net income | -$22.0M |
| Operating income | Not in SEC XBRL data |
| Net margin | -28.4% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.0× |
Reported in ILS; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2022-06-23 |
| Latest annual report | 20-F | 2026-04-30 |
| Latest quarterly / interim | 6-K | 2026-09-08 |
Source: SEC EDGAR submissions feed, 119 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ACRV | Acrivon Therapeutics Inc. | $1.75 | -7.89% | $75.0M |
| LFVN | Lifevantage Corporation Common Stock (Delaware) | $5.95 | -0.50% | $74.9M |
| HRTX | Heron Therapeutics Inc. | $0.3906 | -6.01% | $74.2M |
| MNOV | Medicinova Inc | $1.50 | -2.60% | $73.8M |
| NTHI | NeOnc Technologies Holdings Inc. | $2.60 | -4.95% | $77.2M |
| CTOR | Citius Oncology Inc. | $0.7920 | -2.54% | $73.6M |
| RFL | Rafael Holdings Inc. | $1.49 | -1.97% | $77.5M |
| PMN | ProMIS Neurosciences Inc. Common Shares (ON) | $8.66 | -8.36% | $77.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier